हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Peter James
Organ-on-chip (OoC) technology allows building complex in vitro models tailored specifically to the tissue/organ needs. OoC models mimic the microphysiological environment cells experience in a tissue including the vasculature-like perfusion. They are developed to potentiate several functional readouts using very low cell numbers. Over the past years, the technology has emerged as a powerful tool to support drug discovery and development with a potential for pharmaceutical R&D cost reduction1. The rise of complex treatment modalities, increasing attrition rates and low of predictively of current model systems created an urgent need for human-relevant and wellcharacterized in vitro models to support drug development (i) in efficacy testing by building in vitro disease models and (ii) in toxicity testing by providing a unique tool for mechanistic studies. Of particular interest for both efficacy and toxicity testing, is the human eye. Millions of people worldwide are affected by ocular disorders leading to visual impairment. Hence, to develop ophthalmic drugs and study ocular toxicity, novel human-relevant ocular tissue models are urgently needed.